PuSH - Publikationsserver des Helmholtz Zentrums München

Gut hormone polyagonists for the treatment of type 2 diabetes.

Peptides 100, 190-201 (2018)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Chemical derivatives of the gut-derived peptide hormone glucagon-like peptide 1 (GLP-1) are among the best-in-class pharmacotherapies to treat obesity and type 2 diabetes. However, GLP-1 analogs have modest weight lowering capacity, in the range of 5-10%, and the therapeutic window is hampered by dose-dependent side effects. Over the last few years, a new concept has emerged: combining the beneficial effects of several key metabolic hormones into a single molecular entity. Several unimolecular GLP-1-based polyagonists have shown superior metabolic action compared to GLP-1 monotherapies. In this review article, we highlight the history of polyagonists targeting the receptors for GLP-1, GIP and glucagon, and discuss recent progress in expanding of this concept to now allow targeted delivery of nuclear hormones via GLP-1 and other gut hormones, as a novel approach towards more personalized pharmacotherapies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.851
0.971
57
67
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Glp-1/glucagon Co-agonism ; Polypharmacology ; Type 2 Diabetes ; Gip; Dependent Insulinotropic Polypeptide; Gastric-inhibitory Polypeptide; Glucagon-like Peptide-1; Term Weight Control; Glp-1 Receptor Agonists; High-fat Diet; Topiramate Extended-release; Prohormone Convertase Pc2; Pancreatic Beta-cells; In-vivo
Sprache englisch
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 0196-9781
e-ISSN 1873-5169
Zeitschrift Peptides
Quellenangaben Band: 100, Heft: , Seiten: 190-201 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort New York, NY
Begutachtungsstatus Peer reviewed
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
Scopus ID 85041458811
PubMed ID 29412819
Erfassungsdatum 2018-03-12